Key statistics
On Friday, Catalyst Pharmaceuticals Inc (CN2:BER) closed at 21.28, -0.56% below its 52-week high of 21.40, set on Nov 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.28 |
---|---|
High | 21.28 |
Low | 21.28 |
Bid | 22.28 |
Offer | 22.35 |
Previous close | 21.40 |
Average volume | 172.80 |
---|---|
Shares outstanding | 119.27m |
Free float | 112.14m |
P/E (TTM) | 20.42 |
Market cap | 2.85bn USD |
EPS (TTM) | 1.17 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 07:08 GMT.
More ▼
- Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
- Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
- Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
- Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
- Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
- Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
- Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
- Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
- Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
- Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
More ▼